Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Diabetes Care

• Publication date

  2018-01-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc17-1589PMID 29298800
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pemafibrate: First Global Approval

  2017cited by this paper
• Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.

  2017cited by this paper
• Selective peroxisome proliferator‐activated receptor‐α modulator K‐877 efficiently activates the peroxisome proliferator‐activated receptor‐α pathway and improves lipid metabolism in mice

  2017cited by this paper
• Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.

  2017cited by this paper
• Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.

  2017cited by this paper
• Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

  2016cited by this paper
• The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.

  2016cited by this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention

  2016cited by this paper
• Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

  2016cited by this paper
• Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

  2016cited by this paper
• Excess Mortality among Persons with Type 2 Diabetes.

  2016influential reference
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

  2016cited by this paper
• Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver.

  2015cited by this paper
• Pathophysiology of diabetic dyslipidaemia: where are we?

  2015influential reference
• Excess Mortality among Persons with Type 2 Diabetes.

  2015cited by this paper
• Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study

  2014cited by this paper
• Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study

  2014cited by this paper
• The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.

  2014cited by this paper
• The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.

  2013cited by this paper
• Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

  2013cited by this paper
• Abstract 12867: The Mechanism of K-877, a Highly Potent and Selective Pparalpha Modulator, on Regulation of Synthesis, Secretion and Metabolism of Triglycerides and Cholesterol

  2013cited by this paper
• Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.

  2011cited by this paper
• Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS).

  2011cited by this paper
• [The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus].

  2010cited by this paper
• Effects of combination lipid therapy in type 2 diabetes mellitus.

  2010cited by this paper
• Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice.

  2010cited by this paper
• Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome

  2009cited by this paper
• Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

  2009cited by this paper
• Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database

  2008cited by this paper
• Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome

  2008cited by this paper
• Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

  2008cited by this paper
• Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus

  2007cited by this paper
• Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.

  2007cited by this paper
• Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann–Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein

  2006cited by this paper
• Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid (LY518674), That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression

  2005cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

  2004cited by this paper
• Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

  2002cited by this paper
• Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.

  2001cited by this paper
• MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION

  2000cited by this paper
• United Kingdom Prospective Diabetes Study(UKPDS)からのメッセージとその解釈

  1999cited by this paper
• Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

  1998cited by this paper
• Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

  1998cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper

• Normal triglyceride levels are positively associated with plasma glucose levels and type 2 diabetes diagnosis in Chinese adults

  2026cites this paper
• Nutritional composition, phytochemistry, and mechanistic insights into the health-promoting properties of Termitomyces robustus: A comprehensive review

  2026cites this paper
• Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders

  2025cites this paper
• Mercury-induced neurotoxicity in rat: in vivo and in silico studies of thymoquinone modulatory effect via oxidative stress and inflammation, HO-1/NRF/Trx/Trx-R trajectories

  2025cites this paper
• Fibrates : Do They Still Have a Role in Therapy in 2025?

  2025cites this paper
• Pemafibrate Improves Lipid and Liver Metabolism in Adult GH Deficiency: A Prospective Observational Study

  2025cites this paper
• Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights.

  2025cites this paper
• Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions

  2025cites this paper
• Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and updated meta-analysis of randomized controlled trials

  2025cites this paper
• Impact of Lipid and ASCVD-Modulating Agents on Glycemia and New-Onset Diabetes or Prediabetes

  2025cites this paper
• Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data

  2025cites this paper
• Regulation of UCP1 expression by PPARα and pemafibrate in human beige adipocytes.

  2025cites this paper
• Selective PPARα Modulator (SPPARMα) in the Era of the MASLD Pandemic: Current Insights and Future Prospects.

  2025cites this paper
• Factors associated with severe lower extremity artery disease in type 2 diabetes based on a large scale claims database in Japan

  2025cites this paper
• Long-Term Safety and Efficacy of Pemafibrate to Treat Hyperlipidemia: Post-marketing Surveillance Over a 24-Month Observation Period in Japan

  2025cites this paper
• Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome

  2024cites this paper
• Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol

  2024cites this paper
• The Effect of Adjuvant Therapy on Metabolic Syndrome in Schizophrenia Patients at Madani Hospital

  2024cites this paper
• Role of MASLD in CVD: A review of emerging treatment options.

  2024cites this paper
• Factor affecting severe atherothrombotic cerebral infarction in patients with type 2 diabetes mellitus: Large‐scale claim database analysis of Japan

  2024cites this paper
• Mechanisms of Abnormal Lipid Metabolism in the Pathogenesis of Disease

  2024cites this paper
• Lessons from PROMINENT and prospects for pemafibrate

  2024cites this paper
• Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies

  2024cites this paper
• New Advances in Lipid Interventions under Stratified Management of Atherosclerotic Cardiovascular Disease

  2024cites this paper
• MASLD/MASH and type 2 diabetes: two sides of the same coin? From single PPAR to pan-PPAR agonists.

  2024cites this paper
• Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial

  2024cites this paper
• Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial.

  2024cites this paper
• Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial

  2024cites this paper
• Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study

  2024cites this paper
• Pemafibrate Effectively Reduced Triglycerides in Patients with a History of PCI or CABG

  2024cites this paper
• An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α

  2023cites this paper
• Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients

  2023cites this paper
• Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia

  2023cites this paper
• Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease

  2023cites this paper
• Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review

  2023cites this paper
• The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases

  2023cites this paper
• Treating NASH by targeting peroxisome proliferator-activated receptors.

  2023cites this paper
• Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study

  2023cites this paper
• Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease

  2023cites this paper
• Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study

  2023cites this paper
• Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

  2023influential citation
• Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease

  2023cites this paper
• Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.

  2023cites this paper
• Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome

  2023cites this paper
• Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)

  2023cites this paper
• Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio

  2022cites this paper
• Management of Patients with Type V Hyperlipoproteinemia: An Uncommon Phenotype of Dyslipidemia with Chylomicronemia and Severe Hypertriglyceridemia

  2022influential citation
• Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events

  2022cites this paper
• Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

  2022cites this paper
• Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: a multi-center prospective observational study, the PARM-T2D study.

  2022cites this paper
• Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia

  2022cites this paper
• A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR).

  2022cites this paper
• Retinal degeneration induced in a mouse model of ischemia–reperfusion injury and its management by pemafibrate treatment

  2022cites this paper
• Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature

  2022cites this paper
• Management of Mild-to-Moderate Hypertriglyceridemia.

  2022cites this paper
• PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

  2022influential citation
• The Lipid Profiles in Different Characteristics of Women with PCOS and the Interaction Between Dyslipidemia and Metabolic Disorder States: A Retrospective Study in Chinese Population

  2022cites this paper
• Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

  2022cites this paper
• Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study

  2022cites this paper
• Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.

  2022cites this paper
• New therapeutic approaches for the treatment of hypertriglyceridemia

  2022cites this paper
• Event Monitoring and Evaluation by Community Pharmacists in Japan: A Pilot Study on Fenofibrate and Pemafibrate

  2022cites this paper
• The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment

  2022cites this paper
• Metabolic Variation Dictates Cardiac Pathogenesis in Patients With Tetralogy of Fallot

  2022cites this paper
• Real ambient particulate matter-induced lipid metabolism disorder: Roles of peroxisome proliferators-activated receptor alpha.

  2022cites this paper
• Diabetic dyslipidaemia

  2021cites this paper
• Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

  2021cites this paper
• Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy

  2021cites this paper
• Strain-Specific Effects of Bifidobacterium longum on Hypercholesterolemic Rats and Potential Mechanisms

  2021cites this paper
• Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate

  2021cites this paper
• Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

  2021cites this paper
• Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study

  2021cites this paper
• Pemafibrate suppresses oxidative stress and apoptosis under cardiomyocyte ischemia-reperfusion injury in type 1 diabetes mellitus

  2021cites this paper
• Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice

  2021cites this paper
• Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review

  2021cites this paper
• The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD

  2021cites this paper
• Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

  2021cites this paper
• Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes

  2021cites this paper
• PPAR control of metabolism and cardiovascular functions

  2021cites this paper
• Anti-diabetic drugs and NASH: from current options to promising perspectives

  2021cites this paper
• Effect of Lactobacillus fermentum TKSN041 on improving streptozotocin-induced type 2 diabetes in rats.

  2021cites this paper
• Working towards full eradication of lipid-driven cardiovascular risk?

  2021cites this paper
• Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention

  2021cites this paper
• Deficiency of peroxisome proliferator-activated receptor α attenuates apoptosis and promotes migration of vascular smooth muscle cells

  2021cites this paper
• Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?

  2021cites this paper
• Tratamiento actual de la hipertrigliceridemia

  2021cites this paper
• Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline

  2021cites this paper
• Role of Vitamin B12 and Folate in Metabolic Syndrome

  2021cites this paper
• Hypertriglyceridaemia: contemporary management of a neglected cardiovascular risk factor

  2021cites this paper
• Current treatment of hypertriglyceridemia

  2021cites this paper
• Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis

  2020cites this paper
• Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH

  2020cites this paper
• An Increased Plasma Level of ApoCIII-Rich Electronegative High-Density Lipoprotein May Contribute to Cognitive Impairment in Alzheimer’s Disease

  2020cites this paper
• A spotlight on the surfacing of self-management of employees with diabetes seen by professional nurses in selected occupational health clinics in Cape Town

  2020cites this paper
• DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism

  2020cites this paper
• Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap

  2020cites this paper
• High-Density Lipoproteins

  2020cites this paper
• Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease.

  2020cites this paper
• Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy

  2020cites this paper
• Cardiomyopathy in obesity, insulin resistance and diabetes

  2020cites this paper